Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

57
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
57
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
Vascular Spasm01:16

Vascular Spasm

2.5K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On-demand peptide therapeutics for multi-year space exploration: analysis of clinical and operational relevance and recombinant production feasibility.

NPJ microgravity·2026
Same author

Hyperacute Interleukin-1β Production and Neutrophil Extracellular Trap Formation in the Cerebral Circulation of Stroke Patients with Large Vessel Occlusion.

Annals of neurology·2026
Same author

Circulating biomarkers improve prediction of postoperative outcome after aortic valve surgery.

Frontiers in cardiovascular medicine·2026
Same author

Extracellular traps from myeloid cells as therapeutic targets in traumatic heterotopic ossification.

Science translational medicine·2026
Same author

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition.

International journal of cancer·2026
Same author

Linking rare variants to cell-type function in profound autism with brain transcriptomics and foundation models.

Cell genomics·2026

Related Experiment Video

Updated: Oct 15, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.4K

An update on factor XII-driven vascular inflammation.

Reiner K Mailer1, Chandini Rangaswamy1, Sandra Konrath1

  • 1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Biochimica Et Biophysica Acta. Molecular Cell Research
|October 26, 2021
PubMed
Summary
This summary is machine-generated.

Factor XII (FXII) initiates proteolytic cascades and drives vascular inflammation, impacting endothelial dysfunction and atherosclerosis. FXII deficiency protects against thrombosis without adverse effects, highlighting its therapeutic potential.

Keywords:
Cardiovascular diseaseContact activationContact systemEndothelial dysfunctionFactor XIIThrombo-inflammation

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.2K

Related Experiment Videos

Last Updated: Oct 15, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.2K

Area of Science:

  • Biochemistry
  • Vascular Biology
  • Immunology

Background:

  • Factor XII (FXII) is a liver-derived zymogen activating serine protease FXIIa, initiating proteolytic cascades.
  • FXII(a) activity is modulated by cellular receptors, surfaces, proteases, and inhibitors, binding specific protein domains.
  • FXIIa initiates pro-inflammatory and pro-thrombotic pathways, implicated in endothelial dysfunction.

Purpose of the Study:

  • To review current understanding of FXII(a)-driven vascular inflammation.
  • To focus on endothelial hyperpermeability, receptor signaling, atherosclerosis, and immune cell activation.

Main Methods:

  • Literature review of current concepts on FXII(a)-mediated vascular inflammation.
  • Analysis of FXIIa's role in pathological states beyond thrombosis.

Main Results:

  • FXIIa plays a key role in thrombo-inflammation and endothelial dysfunction.
  • Elevated FXIIa levels correlate with hypercholesterolemia and hypertriglyceridemia.
  • FXII deficiency confers protection against thrombosis without adverse clinical outcomes.

Conclusions:

  • FXIIa is a significant contributor to vascular inflammation and associated diseases.
  • Targeting FXIIa may offer therapeutic benefits for thrombotic and inflammatory conditions.
  • Further research into FXIIa's mechanisms is warranted for clinical applications.